RFL News and Press, Rafael Holdings Inc. Class B From 06/16/22

Cranbury, N.J., June 16, 2022 (GLOBE NEWSWIRE) -- Cornerstone Pharmaceuticals, Inc. (“Cornerstone” or the “Company”), a company focused on rare cancer therapeutics and formerly known as Rafael Pharmaceuticals, today announced a publication on preclinical data...

Rafael Holdings press release (NYSE:RFL): Q3 GAAP EPS of -$0.28. Revenue of $0.88M (-11.1% Y/Y). As of April 30, 2022, we had cash, cash equivalents and marketable securities of $59.4 million. For further details see: Rafael Holdings GAAP EPS of -$0.28, revenue of $0.88M

NEWARK, N.J., June 14, 2022 (GLOBE NEWSWIRE) -- Rafael Holdings, Inc. (NYSE: RFL), an early-stage novel cancer and immune metabolism therapeutics company, today reported its financial results for the three and nine months ended April 30, 2022. The Company is focused on accelerating the deve...

In its 34th annual Russell indexes annual reconstitution, following financials/real estates stocks will be added to and deleted from the Russell 3000 Index. While UnitedHealth and Nvidia replaced financial companies JPMorgan Chase and Visa in top 10  largest companies by market cap in Ru...

Cranbury, NJ, June 01, 2022 (GLOBE NEWSWIRE) -- Cornerstone Pharmaceuticals, Inc. (“Cornerstone” or the “Company”), a company focused on rare cancer therapeutics and formerly known as Rafael Pharmaceuticals, today announced that the Company and its partne...

The European Medicines Agency (EMA) granted orphan drug designation to Cornerstone Pharmaceuticals' CPI-613 (devimistat) to treat advanced unresectable biliary tract cancer. Earlier in May, Rafael Pharmaceuticals, a part of Rafael Holdings (NYSE:RFL), had changed its name ...

Cranbury, NJ, May 24, 2022 (GLOBE NEWSWIRE) -- Cornerstone Pharmaceuticals, Inc. (“Cornerstone” or the “Company”), a company focused on rare cancer therapeutics and formerly known as Rafael Pharmaceuticals, today announced that the European Medicines Agency (...

Rafael Pharmaceuticals (NYSE:RFL) announced that it is changing its name to Cornerstone Pharmaceuticals, its original company name. New trials in the pipeline for hematologic and solid tumors will launch in Q2 and Q3 2022.  The company's clinical trials in Burkitt's lymphoma, b...

Cranbury, NJ, May 19, 2022 (GLOBE NEWSWIRE) -- Rafael Pharmaceuticals, Inc. (“Rafael” or the “Company”), a company focused on the development of rare cancer therapeutics, today announced that it is changing its name to Cornerstone Pharmaceuticals, Inc. ( ...

Kahn Brothers’ 13F portfolio value increased from $741M to $788M this quarter. Citigroup, ViewRay, and VOXX International were increased during the quarter. The portfolio continues to be very concentrated with the top five positions accounting for ~48% of the 13F holdings. ...